NKGen Biotech

NKGen Biotech Net Tangible Assets

The Net Tangible Assets of NKGen Biotech (NKGN) as of Nov 22, 2026 is -58.79 M USD. In the previous year, Net Tangible Assets was 1.56 M USD — a change of -3,861.04% (lower).

Net Tangible Assets

-58.79 MUSD

YoY

-3,861.04%

Last updated:

Net Tangible Assets of NKGen Biotech is 2023 -58.79 M USD. Net Tangible Assets of NKGen Biotech was 2022 1.56 M USD. It decreases by -3,861.04% lower compared to the previous year.

The NKGen Biotech Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2021
-38.05 M USD
Jan 1, 2022
1.56 M USD
Jan 1, 2023
-58.79 M USD
The NKGen Biotech Net Tangible Assets history
YEARNet Tangible AssetsYoY
-58.79 MUSD-3,861.04%
1.56 MUSD-104.11%
-38.05 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech Stock analysis

What does NKGen Biotech do? NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage. NKGen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NKGen Biotech stock

Net Tangible Assets of NKGen Biotech is -58.79 M USD in 2023.

Net Tangible Assets of NKGen Biotech changed from 1.56 M USD to -58.79 M USD, representing a -3,861.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets NKGen Biotech since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's NKGen Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — NKGen Biotech

All Key Metrics — NKGen Biotech